
Verge Genomics - Tech Innovator Profile
Description
Verge Genomics - Tech Innovator Profile
Summary
Founded in 2015, Verge Genomics is an AI-driven biopharmaceutical drug discovery company that applies patient genomes, epigenomics, and gene expression for identifying novel effective drugs; stratify patient subpopulations, and therapeutic gene targets for accelerating clinical success. Verge Genomics is focusing on three neurodegenerative diseases: frontotemporal dementia (FTD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS).
Scope
The report provides information and insights into Verge Genomics, including -
Summary
Founded in 2015, Verge Genomics is an AI-driven biopharmaceutical drug discovery company that applies patient genomes, epigenomics, and gene expression for identifying novel effective drugs; stratify patient subpopulations, and therapeutic gene targets for accelerating clinical success. Verge Genomics is focusing on three neurodegenerative diseases: frontotemporal dementia (FTD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS).
Scope
The report provides information and insights into Verge Genomics, including -
- Overview of the company and its product offering
- Detailed insight into its business model, company type and headquarter
- Information on funding and partnership
- Biography of top management
- Gain insights into Verge Genomics' business operations.
- Gain insights into partnership and funding.
- Gain understanding about its technology focus.
Table of Contents
10 Pages
- Overview
- Technology Focus
- Product Overview
- Partnerships & Funding
- Key Employees
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.